| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥338.4B | ¥339.8B | -0.4% |
| Operating Income | ¥18.9B | ¥19.3B | -2.3% |
| Ordinary Income | ¥22.2B | ¥25.5B | -13.0% |
| Net Income | ¥20.4B | ¥14.8B | +38.0% |
| ROE | 3.9% | 2.9% | - |
FY2026 Q1 results showed revenue of 33,842 million yen (YoY -0.4%, -149 million yen), operating income of 1,887 million yen (YoY -2.3%, -44 million yen), ordinary income of 2,216 million yen (YoY -13.0%, -330 million yen), and net income of 2,040 million yen (YoY +38.0%, +562 million yen). Revenue remained flat while operating income declined modestly, but net income increased significantly driven by extraordinary gains of 1,014 million yen from investment securities sales (939 million yen). The disconnect between declining ordinary income and rising net income reflects the material contribution of non-recurring items. Progress against full-year guidance stands at 26.0% for revenue and 30.4% for operating income, tracking ahead of the typical Q1 baseline of 25%.
Revenue performance was essentially flat at -0.4%, with mixed results across segments: Fine Chemicals declined 1.8%, Industrial Products grew 0.6%, Sustainability expanded 11.5%, and Life Sciences contracted 3.3%. The revenue stability masks underlying segment dynamics, with EMAS SUPPLIES & SERVICES PTE. LTD. (acquired September 2025) contributing to consolidated revenue for the first time, offsetting weakness in Life Sciences and Fine Chemicals.
Operating income declined 2.3% to 1,887 million yen, pressured by selling, general and administrative expenses rising 3.5% YoY to 3,995 million yen, outpacing revenue growth. Gross profit margin improved modestly to 17.4% from 17.0% YoY, but was insufficient to offset the SG&A increase. Operating margin compressed to 5.6% from 5.7% in the prior year.
The gap between operating income (1,887 million yen) and ordinary income (2,216 million yen) reflects 378 million yen in non-operating income, primarily foreign exchange gains of 306 million yen that provided earnings support. Ordinary income declined 13.0% YoY as the prior period benefited from higher non-operating gains.
The substantial divergence between ordinary income (2,216 million yen) and net income (2,040 million yen) stems from extraordinary items. Special gains totaled 1,014 million yen, predominantly from investment securities sales of 939 million yen, which boosted pre-tax income to 3,230 million yen and drove the 38.0% increase in net income. This represents a non-recurring factor that inflated earnings quality.
The quarterly results demonstrate a "revenue flat, profit down (operating), profit up (net)" pattern, where core business profitability weakened slightly due to cost pressures, but extraordinary gains masked the underlying trend and produced headline net income growth.
Fine Chemicals generated revenue of 11,067 million yen (-1.8% YoY) and operating income of 733 million yen (+2.6% YoY), representing an operating margin of 6.6%. Despite revenue contraction, profit expanded through sales price adjustments and favorable rubber material demand in the domestic market. Chemicals faced weak demand from market conditions but maintained profitability through pricing discipline. Overseas group company revenue declines pressured segment performance.
Industrial Products, the core business by revenue at 9,699 million yen (+0.6% YoY), delivered operating income of 866 million yen (+3.3% YoY) with an 8.9% operating margin, the highest among segments. This segment drove profit growth for the quarter. Domestic sales benefited from price revisions, while overseas sales expanded via strong Thai exports and the consolidation of EMAS, which contributed to consolidated earnings in its first year. Foreign exchange tailwinds also supported profit expansion. China operations declined due to reduced production at Japanese automakers.
Sustainability recorded revenue of 2,704 million yen (+11.5% YoY) but operating income fell to 258 million yen (-12.8% YoY), yielding a 9.5% operating margin. The segment achieved strong revenue growth from feed processing equipment consumables and large-scale wood biomass projects, but profitability declined during a transitional phase in marine development-related business and reduced geothermal equipment sales. Oil and gas equipment sales remained robust.
Life Sciences posted revenue of 10,011 million yen (-3.3% YoY) and operating income of 484 million yen (-22.9% YoY), with operating margin compressing to 4.8%. While electrical materials exports, functional feed ingredients, and scientific equipment showed recovery, the segment was materially impacted by the termination of bio-related equipment contracts at Scrum, causing the sharp profit decline.
Segment margin differentials are material: Sustainability leads at 9.5%, Industrial Products at 8.9%, Fine Chemicals at 6.6%, and Life Sciences trails at 4.8%. The core Industrial Products segment not only delivered profit growth but exhibited superior margin resilience, underscoring its importance to consolidated profitability.
Profitability: ROE of 3.9% remains below the company's 3-year historical range, reflecting capital efficiency challenges. Operating margin of 5.6% declined 0.1pt YoY. Net profit margin of 6.0% was elevated by extraordinary gains but operating-based profitability remains constrained by SG&A expense growth outpacing revenue.
Cash Quality: Operating cash flow data is not disclosed in Q1 materials, limiting OCF/Net Income ratio assessment. However, working capital metrics raise concerns: inventory of 28,087 million yen (33.6% of total assets), receivables of 21,866 million yen, days inventory outstanding of 373 days, and days sales outstanding of 236 days indicate cash conversion cycle of 434 days, signaling substantial capital tied up in operations and potential earnings quality issues.
Investment: Capital expenditure and depreciation/amortization figures are not disclosed for Q1, preventing CapEx/D&A ratio calculation. Goodwill increased 1,202 million yen (+178.4%) and intangible assets rose 1,206 million yen (+92.3%), both attributable to the EMAS acquisition, indicating active M&A investment.
Financial Health: Equity ratio of 63.0% (527,820 million yen equity against 836,587 million yen total assets) reflects strong capitalization. Current ratio of 247.1% and quick ratio of 150.3% demonstrate robust short-term liquidity. However, short-term liabilities represent 97.3% of total liabilities, creating refinancing concentration risk. Interest-bearing debt of 3,752 million yen remains modest at 7.2% of total assets, and interest coverage of 94.35x indicates minimal financial burden.
Operating CF: Not disclosed in Q1 materials. Given net income of 2,040 million yen, the absence of OCF data prevents direct assessment of cash-backed earnings quality. Working capital indicators (DIO 373 days, DSO 236 days, CCC 434 days) suggest material cash consumption from inventory buildup and extended receivables collection, likely constraining operating cash generation.
Investing CF: Not separately disclosed. The acquisition of EMAS resulted in goodwill of 1,202 million yen and intangible assets of 1,206 million yen, representing significant acquisition-related outflows during the period. Investment securities sales generated 939 million yen in proceeds (recorded as extraordinary gain), providing cash inflow.
Financing CF: Not separately disclosed. Short-term borrowings increased 742 million yen (+25.5%) to 3,654 million yen, indicating incremental debt drawdown likely to fund working capital and M&A-related needs.
FCF: Cannot be calculated due to lack of CapEx disclosure. The combination of high dividend payout ratio (calculated at 81.1% based on full-year dividend guidance of 57 yen per share against Q1 annualized EPS), working capital intensity, and M&A spending suggests limited free cash flow generation capacity.
Cash generation: Needs Monitoring. Extended working capital cycles and high capital intensity in operations, combined with elevated payout ratio and M&A activity, warrant close scrutiny of cash generation sustainability in subsequent quarters.
Ordinary vs Net Income: Net income of 2,040 million yen substantially exceeded ordinary income of 2,216 million yen after accounting for extraordinary items. Special gains of 1,014 million yen (primarily investment securities sales of 939 million yen, representing 2.8% of revenue) materially inflated net income by approximately 50%. Excluding these non-recurring items, normalized net income would approximate 1,400-1,500 million yen, below the prior year's 1,480 million yen. The 38.0% headline net income growth is therefore non-sustainable.
Non-operating income of 378 million yen included foreign exchange gains of 306 million yen (0.9% of revenue), providing modest earnings support subject to FX volatility. Non-operating expenses were limited, resulting in ordinary income exceeding operating income by 329 million yen.
Accruals: While OCF data is unavailable, balance sheet changes indicate significant accrual concerns. Inventory increased, receivables remain elevated (DSO 236 days), and working capital metrics suggest earnings are not translating efficiently to cash. The extended cash conversion cycle of 434 days implies substantial negative operating working capital changes, likely resulting in OCF trailing net income materially. This represents a clear earnings quality warning signal.
The quality of reported earnings is compromised by reliance on non-recurring gains and apparent low cash realization, requiring investors to focus on normalized operating profitability and cash flow trends in evaluating sustainable earnings power.
Full-year guidance (announced November 10, 2025) remains unchanged: revenue of 130,000 million yen (-2.0% YoY), operating income of 6,200 million yen (-3.6% YoY), ordinary income of 6,500 million yen (-5.5% YoY), and net income of 4,100 million yen. Annual dividend is projected at 57 yen per share (interim 28 yen, year-end 29 yen).
Progress rate against full-year targets: Revenue 26.0%, operating income 30.4%, ordinary income 34.1%, and net income 49.8%. Operating income progress of 30.4% exceeds the typical Q1 baseline of 25% by 5.4 percentage points, indicating favorable early-stage execution. Net income progress of 49.8% is significantly ahead due to Q1 extraordinary gains, which are unlikely to recur proportionally in remaining quarters.
The company's decision to maintain full-year guidance despite strong Q1 operating income progress suggests management conservatism or anticipates headwinds in subsequent quarters. Key considerations include: (1) whether SG&A expense pressures will intensify, (2) segment profit sustainability, particularly in Life Sciences which declined 22.9%, and (3) FX and non-operating income variability.
For Q2-Q4, the company must generate operating income of 4,313 million yen (69.6% of full-year target) across nine months, implying a quarterly run rate of 1,438 million yen, below the Q1 level of 1,887 million yen. This suggests anticipated normalization or margin pressure ahead. Net income guidance of 4,100 million yen implies approximately 2,060 million yen in remaining quarters without further extraordinary gains, requiring stable core profitability.
The operating income guidance trajectory warrants monitoring for potential upward revision if Q2 sustains Q1 momentum; conversely, net income faces downside risk absent additional non-recurring gains.
The company plans an annual dividend of 57.0 yen per share, consisting of an interim dividend of 28.0 yen and a year-end dividend of 29.0 yen. Based on Q1 basic EPS of 70.83 yen (annualized to 283.32 yen) and net income of 2,040 million yen (annualized to 8,160 million yen), the implied dividend payout ratio calculates to 81.1% against Q1 annualized earnings.
However, adjusting for full-year net income guidance of 4,100 million yen and EPS guidance of 142.31 yen, the planned dividend of 57.0 yen represents a payout ratio of 40.1%, which is sustainable relative to normalized earnings. The Q1 calculation is distorted by extraordinary gains inflating the period's net income.
Free cash flow coverage of dividends cannot be assessed due to lack of FCF disclosure, but working capital intensity (CCC 434 days) and elevated inventory/receivables suggest cash generation may lag earnings. With cash and deposits of 31,547 million yen and short-term liquidity ratios above 200%, the company maintains adequate liquidity to support dividends in the near term, but sustained high payout relative to cash generation warrants scrutiny.
No share buyback program has been announced or disclosed for the fiscal year. Total shareholder return is therefore limited to dividends at this time. The 40% payout ratio based on full-year guidance is moderate and sustainable if operating cash flow normalizes, but the company's capital allocation leaves limited room for incremental growth investment or shareholder returns expansion.
Near-term:
Long-term:
Industry Position (Reference - Proprietary Analysis)
Profitability: Operating margin of 5.6% positions below the company's own 3-year range and reflects ongoing pressure from SG&A expense growth. Net profit margin of 6.0% is elevated by non-recurring gains. The company's historical operating margin stability around 5.6-5.7% suggests limited operating leverage.
Growth: Revenue growth of -0.4% YoY indicates stagnation relative to the company's recent trajectory. Full-year guidance projects revenue contraction of -2.0%, signaling headwinds in core markets. The flat revenue trend requires monitoring against peer growth rates in trading and distribution sectors.
Efficiency: Asset turnover of 0.405x reflects capital-intensive working capital structure, with inventory and receivables consuming 33.6% and 26.1% of assets respectively. This indicates room for improvement in operational efficiency relative to industry norms for trading companies.
Financial Health: Equity ratio of 63.0% demonstrates strong capitalization exceeding typical trading company standards. Interest coverage of 94.35x and debt-to-capital ratio of 6.6% reflect conservative leverage, providing financial flexibility.
Note: Industry benchmark comparisons are reference information derived from proprietary analysis of publicly available earnings data. Sector-specific context for diversified trading companies with chemical, industrial, and life science segments suggests the company's profitability and efficiency metrics warrant ongoing operational focus.
Working Capital Risk: Inventory of 28,087 million yen (33.6% of total assets) with days inventory outstanding of 373 days and cash conversion cycle of 434 days create significant liquidity strain and inventory obsolescence risk. Extended working capital cycles constrain cash generation and limit financial flexibility. If demand weakens or product lifecycles shorten, inventory write-downs could materially impact profitability. The sustainability of 81.1% Q1 annualized payout ratio is questionable given working capital intensity.
Refinancing and Liquidity Risk: Short-term liabilities represent 97.3% of total liabilities, creating concentrated refinancing exposure. While current liquidity ratios exceed 200% and cash coverage of short-term debt is 3.15x, any deterioration in credit markets or operating cash flow could constrain refinancing capacity. Short-term borrowings increased 25.5% in Q1, indicating incremental reliance on short-term funding for operations and M&A.
Goodwill and M&A Integration Risk: Goodwill increased 1,202 million yen (+178.4%) and intangible assets rose 1,206 million yen (+92.3%) from the EMAS acquisition. While EMAS contributed to consolidated earnings in its first year, the realization of acquisition synergies and goodwill recoverability remain uncertain. Failure to achieve projected returns or adverse business conditions in EMAS operations could trigger impairment charges. The company's M&A track record and integration execution will be critical to protecting shareholder value from acquisition-related write-downs.
Key Takeaways from Earnings:
Operating profitability remains under pressure with modest revenue contraction and operating income decline of 2.3%, driven by SG&A expense growth outpacing sales. The core business performance is stable but not expanding, with operating margin compression to 5.6%. The 38.0% headline net income growth is attributable to non-recurring investment securities sales of 939 million yen, masking underlying earnings weakness. Normalized earnings power is lower than reported, requiring focus on sustainable operating trends rather than headline figures.
Segment dynamics reveal Industrial Products as the profit growth driver, with EMAS acquisition contributing immediately to consolidated earnings and demonstrating early M&A success. Life Sciences segment profit declined sharply (-22.9%) due to contract terminations, creating a drag that must be addressed. Sustainability segment revenue growth (+11.5%) was offset by margin contraction, indicating project mix or cost challenges. Segment margin dispersion from 4.8% to 9.5% highlights portfolio optimization opportunities.
Capital efficiency and cash generation remain critical concerns. ROE of 3.9% is low, working capital metrics (CCC 434 days) indicate significant operational inefficiency, and the absence of disclosed operating cash flow limits visibility into cash earnings quality. The combination of high dividend payout (40% on full-year guidance, 81% on Q1 annualized), elevated working capital, and M&A investment creates cash flow sustainability questions. Short-term debt reliance (97.3% of liabilities) adds refinancing risk. Improvement in inventory turnover, receivables collection, and operating cash flow generation are essential to support dividends and growth investment while maintaining financial flexibility. Progress against full-year guidance of 30.4% for operating income is encouraging but requires validation in subsequent quarters without reliance on extraordinary gains.
This report was automatically generated by AI integrating XBRL earnings data and PDF presentation materials as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.
AI analysis of PDF earnings presentation
Sanyo Trading Co., Ltd.’s FY2026 (fiscal year ending September 2026) first-quarter results were net sales of 338.42 billion yen (YoY -0.4%), operating income of 18.87 billion yen (-2.3%), and ordinary income of 22.16 billion yen (-13.0%). Sales were essentially flat, while operating and ordinary income declined. Meanwhile, due to gains on sales of investment securities, profit attributable to owners of parent rose sharply to 20.40 billion yen (+37.9%). Progress against full-year guidance was solid, with net sales at 26.0% and operating income at 30.4%. By segment, Fine Chemicals posted lower sales and higher profit; Industrial Products recorded higher sales and higher profit; Sustainability and Life Science saw profit decline. Higher SG&A expenses (+3.5%) weighed on operating income.
Gross margin improved by 0.4ppt to 17.4% from 17.0% in the prior-year quarter. Tracking well toward full-year operating income plan of 6.2 billion yen, with 1Q progress at 30.4%. Gains on sales of investment securities of 0.939 billion yen (extraordinary income) significantly boosted net profit. Consolidation of EMAS contributed to profits from the first year in the Industrial Products segment. Equity ratio remained sound at 63.0%.
Full-year guidance is maintained at net sales of 1,300 billion yen, operating income of 6.2 billion yen (operating margin 4.8%), ordinary income of 6.5 billion yen, and profit attributable to owners of parent of 4.1 billion yen. First-quarter progress is on track versus plan, and there is no change to the full-year outlook. The company plans an annual dividend of 57.0 yen (interim 28.0 yen, year-end 29.0 yen).
Management acknowledges the increase in SG&A expenses while expressing confidence in achieving full-year targets. They positively assess the accretive impact from the consolidation of EMAS in the first year. Foreign exchange gains are underpinning ordinary income, and the policy is to pursue full-year goals while adapting to changes in the external environment.
Strengthen overseas operations and consolidate earnings through the acquisition of EMAS (Singapore) as a subsidiary. Improve margins by revising selling prices (Fine Chemicals/Chemicals and Industrial Products in Japan). Sustain robust sales of consumables for feed processing equipment and recognize large-scale woody biomass projects (Sustainability). Expand sales in response to recovering demand for scientific instruments and increase sales volumes of functional feed ingredients (Life Science). Enhance information dissemination and brand awareness through the launch of official social media accounts (Instagram, X).
Impact of production cuts by Japanese automakers due to China’s economic slowdown and intensifying competition (Industrial Products overseas). Softening demand for core products affected by market conditions (Fine Chemicals/Chemicals). Decline in sales and profit due to a lull between projects in marine development-related business (Sustainability). Sales decline from the termination of contracts for bio-related equipment (Life Science). Foreign exchange fluctuations affecting ordinary income (FX gains of 3.06 billion yen lifted results at the ordinary level).